Serving Gainesville,

Lake City, and Ocala, FL

Gainesville – 352-371-2800

 

 Lake City – 386-754-0999

 

 Ocala – 352-867-0045

Vitreo Retinal Associates logo Close-up of an eye

M. Brandon Parrott, M.D., Ph.D.

 

SurgeonVitreoRetinal Associates

June 2017 - present

Gainesville, FL

 

SurgeonCenter for Sight

May 2012 – May 2017

Sarasota, Florida

 

SurgeonTennessee Retina, P.C.,

August 2010 – March 2012

Nashville, Tennessee

 

Instructor      Chief Resident

July 7th, 2009 – July 7th, 2010

Bascom Palmer Eye Institute (BPEI) / University of Miami

Miami, Florida

 

Fellowship Vitreoretinal Fellow

July 7th, 2008 – July 7th, 2009

Bascom Palmer Eye Institute (BPEI) / University of Miami

Miami, Florida

 

Residency Bascom Palmer Eye Institute / Jackson Memorial Health System,

July 1st, 2005 – June 30th, 2008

Miami, Florida

Ophthalmology Residency

 

InternshipChristus St. Joseph Hospital, June 18th, 2004 - June 20th, 2005

Houston, Texas

Transitional Year Internship

 

 

Trust your eyes to our experienced eye care professionals - in business since 1981.

352-371-2800

And introducing Michael Brandon Parrott, M.D., Ph.D, who joined Vitreoretinal Associates in June 2017.

Education

Retinal fellowship: University of Miami, Bascom Palmer Eye Institute, Miami, FL, USA

 

Ophthalmology residency: University of Miami, Bascom Palmer Eye Institute, Miami, FL, USA

 

Internship: Christus St. Joseph Hospital, Houston, TX, USA

 

Medical School: Baylor College of Medicine, Cullen Eye Institute, Houston, TX, US

 

Medical School: Baylor College of Medicine, Cullen Eye Institute, Houston, TX, USA

 

College: University of Tennessee - Knoxville, Knoxville, TN, USA

 

Licensure

State of Florida – Department of Health

Medical Doctor – Active

ME #102018 – Issued 2008

 

State of North Carolina – NC Medical Board

Medical Doctor – Active

Certificate #217718 – Issued 2016  

 

State of Tennessee – Division of Health Related Boards

Medical Doctor – Inactive

MD 45763 – Issued December 2009

 

American Board of Ophthalmology – Board Certified

 

United States Medical Licensing Examination (USMLE) - #5-025-890-4

Step I (Pass / 99 / 258)

Step II (Pass / 99 / 260)

Step III (Pass / 98 / 237)

 

Professional Affiliations

 

 

 

 

 

Honors and Awards

2016 Top Doctor – Castle Connolly

2011Top Ophthalmologist – International Association of Healthcare Professionals

2010-15Compassionate Doctor Award – Patients’ Choice Organization

2005In-service Exam Award – Christus St. Joseph Hospital

2004 Most Outstanding Performance in the Clinical Sciences – BCM MD/PhD program

2004  Alpha Omega Alpha Honor Society - BCM

2002Best Oral Abstract Presentation – Center for Cell and Gene Therapy Symposium – BCM

2001 First Place Poster Presentation – Center for Cell and Gene Therapy Symposium - BCM

2001First Place Outstanding Platform Presentation – Baylor College of Medicine MD/PhD Symposium - BCM

2001First Place Speaker Award – Department of Immunology Student Symposium - BCM

1997Honors for Academic Performance in the Basic Sciences - BCM

1995-2004Presidential Scholarship Award - BCM

1995-2004NIH-Medical Scientist Training Program Fellowship - BCM

1995Chancellor's Citation for Extraordinary Academic Achievement – UTK

1995L. Raymond Shobe Award for Leadership and Academic Excellence in Engineering – UTK

1996Engineering Science and Mechanics Outstanding Student Scholarship - UTK

1994Most active member award - Alpha Epsilon Delta (Pre-medical Honor Society) - UTK

1994Inducted into Tau Beta Pi (Engineering Honor Society)

1990-95      Whittle Scholarship for Leadership and Academic Achievement  - UTK

1990Tennessee Academic Scholar

1990National Merit Finalist

1990 First Place in State of Tennessee in TMTA Advanced Calculus Competition

 

parrott

Publications

Kuriyan, AE, Albini TT, Townsend JH, Rodriguez M, Pandya HK, Leonard RE, Parrott MB, Rosenfeld

Pj, Flynn HW, Goldberg JL: Vision loss after intravitreal injection of autologous “stem cells” for AMD. New England Journal of Medicine 2017: 376:11:1047-1053.

 

Wykoff CC, Parrott MB, Flynn HW Jr, Shi W, Miller D, Alfonso EC:  Nosocomial acute-onset

postoperative endophthalmitis at a university teaching hospital (2002-2009).  American Journal of Ophthalmology 2010: Sep 150(3):392-398.

 

Cavalcante LL, Cavalcante ML, Murray TG, Vigoda MM, Piña Y, Decatur CL, Davis RP, Olmos LC,

Schefler AC, Parrott MB, Alliman KJ, Flynn HW, Moshfeghi AA:  Intravitreal injection analysis at the Bascom Palmer Eye Institute: evaluation of clinical indications for the treatment and incidence rates of endophthalmitis.  Clinical Ophthalmology 2010:  May 25(4):519-524.  

 

Parrott MB:  Evolution of the treatment of neovascular AMD in the age of anti-VEGF agents.  TheOphthalmology Report 2010:  3(3):16-20.

 

Parrott, MB: The evolution of current and future treatments for neovascular AMD.  The

Ophthalmology Report 2009: 2(2):16-20.

 

Campos SK, Parrott MB, Barry MA:  Metabolically biotinylated pIX-modified adenovirus for single-

step affinity purification of viral vectors.  Molecular Therapy 2004: 9(6):942-54.

 

Blum JS, Parrott MB, Mikos AG and Barry MA:  Early osteoblastic differentiation induced by

dexamethasone enhances adenoviral gene delivery to marrow stromal cells.  Journal of Orthopaedic Research 2003: 22(2):411-416.

 

Parrott MB, Adams KE, Mercier GT, Mok H, Campos SK, and Barry MA:  Metabolically biotinylated

adenovirus for cell-targeting, ligand screening, and vector purification.  Molecular Therapy 2003: 8(4):688-700.

 

Takahashi S, Mok H, Parrott MB, Marini FC, Andreeff M, Brenner MK, and Barry MA:  Selection of chronic lymphocytic leukemia targeting peptides.  Cancer Research 2003: 63(17):5213-5217.

 

Barry MA, Campos SK, Ghosh D, Adams KE, Mok H, Mercier GT, and Parrott MB:  Biotinylated

 gene therapy vectors. Expert Opinion in Biological Therapy 2003: 3(6):925-940.

 

Barry MA, Takahashi S, and Parrott MB: Selection of Peptides on Phage. In Vector Targeting for Therapeutic Gene Delivery.  (DT Curiel and JT Douglas Eds.) John Wiley & Sons, Inc. New York, NY 2002.

 

Parrott MB and Barry MA: Metabolic biotinylation of secreted and cell surface proteins from mammalian cells. BBRC 2001: 281:993-1000.

 

Parrott MB and Barry MA: Metabolic biotinylation of recombinant proteins in

mammalian cells and in mice. Molecular Therapy 2000: 1(1):96-104.

Clinical Research Protocols

HAWK - NCT02307682 – Efficacy and Safety of RTH258 Versus Aflibercept - The purpose of this study is to compare RTH258 ophthalmic solution for intravitreal (IVT) injection at two dosage levels to aflibercept solution for IVT injection (2 mg) in subjects with untreated active choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) in the study eye. – Alcon.

 

PROXIMA A - NCT02479386 - Epidemiologic Study of Disease Progression in Patients With

Geographic Atrophy Secondary to Age-Related Macular Degeneration - This study seeks to better characterize relationships between visual function and the progression (worsening) of geographic atrophy (GA) due to age-related macular degeneration (AMD). The study is also intended to generate new information on the relationship between genetics and GA progression. - Hoffmann-La Roche.

 

CEDAR -  NCT02462928 - Safety and Efficacy Study of Abicipar Pegol in Patients With

Neovascular Age-related Macular Degeneration – This is a safety and efficacy study of abicipar pegol in patients with neovascular age-related macular degeneration. – Allergan.

 

ORBIT - NCT02079883 – Ocriplasmin Research to Better Inform Treatment - Multicenter, prospective, observational, Phase 4 study assessing clinical outcomes and safety of JETREA® administered in a real-world setting for the treatment of symptomatic vitreomacular adhesion (VMA) by assessing anatomical and functional outcomes. – Thrombogenics.

 

SHORE – NCT01277302 - A Study Evaluating Dosing Regimens for Treatment With Intravitreal

Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion - This was a Phase IV multicenter, randomized, open-label study, of the efficacy and safety of intravitreal ranibizumab 0.5 mg in subjects with macular edema following Branch Retinal Vein Occlusion (BRVO) or Central Retinal Vein Occlusion (CRVO). – Genentech.

 

FOVEA (FOV2304) - NCT01319487 - Safety and Efficacy Study of Topical Administration

of FOV2304 (High Dose or Low Dose) for the Treatment of Center-involving Clinically Significant Macular Edema Associated With Diabetic Retinopathy - The purpose of the study is to determine whether concentrations of FOV2304 (high dose or low dose) administered in the eye are more effective than placebo in treating patients with diabetic macular edema, following 12 weeks of treatment. - Fovea Pharmaceuticals SA.

 

Novartis HMT –  NCT01542866 - A 16 Week Evaluation of the Novartis Health Management Tool

(HMT) in Age Related Macular Degeneration - This is a prospective pilot study to evaluate the usability and applicability of a self-monitoring test of visual function with the handheld Health Management Tool (HMT) to remotely monitor neovascular Age Related Macular Degeneration (AMD) to detect a potential change in disease status. – Novartis Pharmaceuticals.

 

DODO (FVF4155s) - NCT00533520 -  Evaluation of Dosing Interval of Higher Doses of

Ranibizumab - Phase 4 study to test the safety, tolerability and effectiveness of a higher doses (1.0 mg and 2.0 mg) of ranibizumab versus the standard dose (0.5 mg), in adults with age related macular degeneration who have never been treated with ranibizumab. – Genentech.

 

VISTA - NCT01363440 - Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in

Patients With Diabetic Macular Edema - The purpose of this study is to determine the efficacy of Intravitreal Aflibercept Injection on the best corrected visual acuity (BCVA) in patients with diabetic macular edema (DME) with central involvement.- Regeneron Pharmaceuticals.

 

Foresee Home Device Study (PT US 001) - NCT01334294 – Home Vision Monitoring Using the

ForeseeHome Device Following Treatment of Neovascular Age Related Macular Degeneration. - The purpose of the current study is to evaluate if, in post-treatment patients, PHP parameters as measured with the ForeseeHome are in agreement with clinical decisions and retinal characteristics as measured with optical coherence tomography (OCT). - Notal Vision Ltd.

 

MAHALO – NCT01229215 - A Study of Safety, Tolerability, and Evidence of Activity of  

FCFD4514S Administered Monthly or Every Other Month to Patients With Geographic Atrophy - Phase Ib/II, multicenter, randomized, single-masked, sham-injection-controlled study of safety, tolerability, and evidence of activity of FCFD4514S intravitreal injections administered monthly or every other month in patients with geographic atrophy. – Genentech.

Research Experience

1998-2002 Baylor College of Medicine - Houston, TX

Department of Immunology and the Center for Cell and Gene Therapy

Advisor: Michael A. Barry, Ph.D.

M.D./Ph.D. Candidate - investigated the targeting of retroviral and adenoviral vectors to selected cell types by modifying the viral envelopes and capsid proteins of gene therapy viral vectors

 

1994-1995     University of Tennessee School of Veterinary Medicine - Knoxville, TN

Department of Orthopedic Surgery

Advisor: Jack Wasserman, Ph.D.

Biomedical Engineering Honors Thesis - tested structural integrity and compared biomechanical properties of a novel PMMA trans-hock external fixation device versus a traditional KE stainless-steel fixation device

 

1992-93Oak Ridge National Laboratory - Oak Ridge, TN

Chemical Engineering Division

Consultant - completed uranium contamination resorption project and trained post-doctoral engineer in newly established protocols

 

1992Oak Ridge National Laboratory - Oak Ridge, TN

Chemical Engineering Division

Research Intern - assisted in the design and testing of a biologically based uranium absorption system for the purification of uranium contaminated water

 

1991Oak Ridge National Laboratory - Oak Ridge, TN

Energy Sciences Division

Research Intern - investigated enhancing the efficiency of heat pump technology through innovative design and use of computer models to test the efficiency of prototype heat pumps

Oral Presentations

Nov 2015 Oral Platform Presentation - Vision Loss Consequent to Intravitreal Stem Cell Injection

Albini TA, Kuriyan AE, Townsend JH, Rodriguez M, Pandya HK, Leonard RE, Parrott MB,  Rosenfeld PJ, Flynn HW

2015 Annual Meeting – American Academy of Ophthalmology – Las Vegas, NV

 

Nov 2008 Poster – Nosocomial Acute-onset postoperative endophthalmitis at a university teaching hospital

Wykoff CC, Flynn HW, Miller D, Parrott MB, Murray TG, Smiddy WE, Davis JL  

2008 Annual Meeting – American Academy of Ophthalmology

 

Nov 2007 Poster – Intravitreal bevacizumab use for progressive ROP and Best disease related choroidal neovascular membranes

Parrott MB, Murray, TG, and Berrocal AM

2007 Annual Meeting – American Academy of Ophthalmology  

 

June 2007 Oral Platform Presentation – Nosocomial acute-onset postoperative endophthalmitis survey: An 11-year review of incidence, causative organisms, and outcomes

Parrott MB, Wykoff CC, and Flynn HW

43rd Annual Bascom Palmer Eye Institute Resident’s Day – Miami, FL

 

May 2007 Poster – Nosocomial acute-onset postoperative endophthalmitis survey: An 11-year review of incidence, causative organisms, and outcomes

Parrott MB, Wykoff CC, Miller D, Newton J, and Flynn HW

ARVO 2007 Annual Meeting – Fort Lauderdale, FL

 

June 2003 Oral Platform Presentation – Metabolically Biotinylated Viruses for Vector Targeting and Purification

Campos SK, Parrott MB, Adams KE, and Barry MA

Sixth Annual Meeting of the American Society of Gene Therapy – Washington, DC

 

March 2003 Poster – Metabolically biotinylated gene therapy vectors for vector targeting and purification

Campos SK, Parrott MB, Adams KE, Blum JS, Mok H, Muzykantov V, and Barry MA

Cold Spring Harbor Symposium on Vector Targeting Strategies for Gene Therapy - Cold Spring Harbor, NY

 

March 2003Poster – Selection and application of CLL-targeting peptides using peptide-presenting phage libraries

Takahashi S, Mok H, Parrott MB, Marini FC, Andreeff M, Brenner MK, and Barry MA

Cold Spring Harbor Symposium on Vector Targeting Strategies for Gene Therapy - Cold Spring Harbor, NY

 

Jan. 2003Poster – Apoptosis, mitotic rate, and age correlations in the regression of periorbital hemangiomas

Parrott MB, Font RL, and Chevez-Barrios P

Eighty-Second Annual Texas Society of Pathologists Meeting – Houston, TX

 

June 2002Oral Platform Presentation – Metabolically biotinylated adenoviral vectors for targeted gene therapy

Parrott MB and Barry MA

Fifth Annual Meeting of the American Society of Gene Therapy – Boston, MA

 

May 2002Oral Platform Presentation - Use of in vivo biotinylated adenoviral vectors for targeted gene therapy

Parrott MB and Barry MA

Forty-Third Annual National Student Research Forum – Galveston, TX

 

Dec. 2001Poster - Selection of leukemia-targeting peptides using peptide presenting phage libraries

Takahashi S, Barry ME, Parrott MB, Brenner MK, and Barry MA

Forty-Third American Society of Hematology Annual Meeting - Orlando, FL

 

June 2001Poster - Metabolically biotinylated gene therapy vectors

Parrott MB and Barry MA

Fourth Annual Meeting of the American Society of Gene Therapy - Seattle, WA

 

March 2001Oral Platform Presentation - Metabolically biotinylated adenoviral and retroviral vectors

Parrott MB and Barry MA

Cold Spring Harbor Symposium on Vector Targeting Strategies for Gene Therapy - Cold Spring Harbor, NY

 

June 2000Poster - Metabolic biotinylation of recombinant proteins for viral gene therapy vector targeting  

Parrott MB and Barry MA

Third Annual Meeting of the American Society of Gene Therapy - Denver, CO

 

March 1999Poster - Selecting lung targeting peptides in vivo

Parrott MB and Barry MA

Cold Spring Harbor Symposium on Vector Targeting Strategies for Gene Therapy - Cold Spring Harbor, NY

Teaching Experience

2009-2010        Chief Resident, BPEI

2006-2009 Teaching Assistant for Neuro-Ophthalmology Course, BPEI

1997-2004Teaching Assistant and Graduate Lecturer, Department of Immunology, BCM

2003Conference Leader, Department of Pathology, BCM

1996-1999Conference Leader and Graduate Lecturer, Physiology, BCM

1996-2000Student Affairs Tutor, Biochemistry and Physiology, BCM

1995                  Engineering Specialty Course - Tennessee Governor's School for the Sciences, UTK

Grants and Fellowships 

2003-2004American Medical Association Foundation Research Seed Grant

1999-2002National Research Service Award from National Institutes of Health

1995-2004National Institutes of Health - Medical Scientist Training Program Grant

Professional Organizations 

American Society of Retina Specialists

American Academy of Ophthalmology

Association for Research in Vision and Ophthalmology

Alpha Omega Alpha Honor Medical Society

American Society for Gene Therapy

Tau Beta Pi (Engineering)

American Medical Student Association

Texas Medical Student Association

Texas Society of Pathologists

Baylor Pediatrics Student Association - Research Coordinator

.